Gosselies and Mont-Saint-Guibert, Belgium – Cellistic, the cell therapy development and manufacturing business of Ncardia and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on discovery and development of chimeric antigen receptor T-cell (CAR-T)-based cancer therapeutics, today announced the transaction whereby Cellistic will acquire Celyad Oncology’s cell therapy GMP manufacturing capacity, including the existing building and the related personnel (“The Operational Production Unit”).